<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Signatera &#8211; BIOENGINEER.ORG</title>
	<atom:link href="https://bioengineer.org/tag/signatera/feed/" rel="self" type="application/rss+xml" />
	<link>https://bioengineer.org</link>
	<description>Bioengineering</description>
	<lastBuildDate>Mon, 05 Oct 2026 13:51:10 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=7.1.2</generator>

<image>
	<url>https://bioengineer.org/wp-content/uploads/2019/09/cropped-bioengineering-32x32.png</url>
	<title>Signatera &#8211; BIOENGINEER.ORG</title>
	<link>https://bioengineer.org</link>
	<width>32</width>
	<height>32</height>
</image> 
<site xmlns="com-wordpress:feed-additions:1">72741379</site>	<item>
		<title>Phase III Trial Tests Blood-Based MRD Monitoring to Spare Breast Cancer Patients CDK4/6 Inhibitor Toxicity</title>
		<link>https://bioengineer.org/phase-iii-trial-tests-blood-based-mrd-monitoring-to-spare-breast-cancer-patients-cdk4-6-inhibitor-toxicity/</link>
		
		<dc:creator><![CDATA[]]></dc:creator>
		<pubDate>Mon, 05 Oct 2026 13:51:10 +0000</pubDate>
				<category><![CDATA[Cancer]]></category>
		<category><![CDATA[AFT-70 NAVIGATE]]></category>
		<category><![CDATA[Breast Cancer]]></category>
		<category><![CDATA[CDK4/6 inhibitors]]></category>
		<category><![CDATA[clinical trial]]></category>
		<category><![CDATA[endocrine therapy]]></category>
		<category><![CDATA[ER-positive HER2-negative]]></category>
		<category><![CDATA[giredestrant]]></category>
		<category><![CDATA[Liquid Biopsy]]></category>
		<category><![CDATA[molecular residual disease]]></category>
		<category><![CDATA[precision oncology]]></category>
		<category><![CDATA[SERD]]></category>
		<category><![CDATA[Signatera]]></category>
		<guid isPermaLink="false">https://bioengineer.org/?p=402613</guid>

					<description><![CDATA[The new global phase III AFT-70 NAVIGATE trial will test whether ultrasensitive Signatera MRD blood monitoring can safely guide CDK4/6 inhibitor use in ER-positive/HER2-negative early breast cancer, pairing giredestrant with treatment escalation only when molecular residual disease is detected.]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">402613</post-id>	</item>
	</channel>
</rss>
